Icatibant Pharma Grade API is the acetate salt of a synthetic decapeptide, H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH, supplied as a lyophilized or spray-dried powder for downstream processing into injectable and oral solid dosage forms. The free-base empirical formula C₅₉H₈₉N₁₉O₁₃S corresponds to a monoisotopic mass of 1304.52 Da; the acetate salt is identified by CAS registry number 138614-30-9. The injectable grade is controlled for low bacterial endotoxin and is intended for dissolution to 10 mg/mL subcutaneous solutions, while the oral grade is released under non-sterile microbial limits for tablet, capsule, and granule process development. This API is manufactured under ICH Q7 GMP principles, with residual solvent testing per USP <467>, elemental impurity control aligned to ICH Q3D Option 1, and HPLC purity determination per USP <621>.

The product model designation separates the injectable grade and the oral solid grade because the former requires a low-endotoxin, filter-compatible acetate salt with controlled residual water, while the latter is supplied with a broader microbial specification and may be processed without aseptic containment. For both grades, the route-specific application is not interchangeable; the injectable grade is qualified for solution-state processing and sterile filtration, whereas the oral grade is evaluated for dry blending, granulation, and compression behavior.

How Does the Synthetic Route Influence Purity and Counterion Control?

Solid-phase peptide synthesis of icatibant acetate begins with Fmoc-protected amino acids on a 2-chlorotrityl chloride resin. Coupling is performed by activation with diisopropylcarbodiimide and ethyl cyanohydroxyiminoacetate or similar coupling systems; deprotection is carried out with 20% piperidine in dimethylformamide. Cleavage from the resin with trifluoroacetic acid, triisopropylsilane, and water releases the crude peptide. Preparative reversed-phase HPLC on C₁₈-modified silica, with acetonitrile/water gradients and detection at 210–230 nm, removes deletion peptides, truncated sequences, and diastereomers. The purified trifluoroacetate salt is exchanged to acetate by ion-exchange chromatography or repeated lyophilization from acetic acid; residual trifluoroacetate is controlled as a process impurity. Lyophilization is executed on stainless steel shelf freeze dryers with condenser temperatures below -50 °C and chamber pressure held between 0.1 mbar and 0.2 mbar. The collapse temperature of the amorphous peptide is typically below -20 °C, so primary drying must remain below this threshold to avoid cake collapse and elevated residual water.

Process-scale purification of this decapeptide generates specific impurity profiles that differ from plasma-derived protein preparations. Deletion peptides lacking D-Arg, Hyp, or Oic are monitored by high-resolution LC-MS; oxidation of the thienylalanine side chain is a degradant of interest under oxidative stress. Because the product is synthetic, no human or animal plasma-derived virus inactivation steps are required, and the viral safety risk profile is therefore independent of donor screening. Instead, process-related impurities from solid-phase synthesis require control: residual solvents from cleavage and purification, heavy metals from catalyst residues in peptide synthesis, and counterion mismatch. The acetate content is controlled between 5.0% and 8.0% by ion chromatography; this range avoids excessive pH shift during reconstitution and ensures reproducible salt:peptide stoichiometry. Preparative HPLC fractions are pooled based on analytical HPLC and mass spectrometry; pools with target purity below 98.0% are recycled through a second purification pass. Batch-to-batch variance in residual water and acetate content is controlled through lyophilization cycle limits and nitrogen backfill.

A release specification for a parenteral peptide API of this class integrates compendial general chapters with product-specific HPLC methods. The values below represent typical acceptance criteria for an injectable grade under ICH Q6A; actual batch-specific limits are defined in the approved application.

Method qualification follows ICH Q2(R1) for accuracy, precision, specificity, linearity, and range. Forced degradation studies in acid, base, peroxide, heat, and photolysis identify the main solution-state degradants as oxidized thienylalanine and truncated peptide species. Solid-state stability is maintained when water content remains below 6.0% and the product is stored in sealed Type III glass vials under nitrogen at -20 °C or 2–8 °C; stress data support a provisional retest interval assigned under ICH Q1A(R2).

When Subcutaneous Injection Demands Low Endotoxin and Filtration Compatibility

For injectable formulation, icatibant acetate is dissolved in Water for Injection; pH adjustment with dilute sodium hydroxide or hydrochloric acid targets a final solution concentration of 10 mg/mL. Sterile filtration through 0.2 µm polyethersulfone or polyvinylidene fluoride membranes is used because terminal sterilization can degrade the peptide. Filter binding studies are required at production filter surface area; peptide adsorption to the membrane can reduce delivered dose at low concentrations, and recovery must be confirmed before scale-up. The filtrate is filled into prefilled syringes under aseptic conditions. Container closure integrity is evaluated by dye ingress or vacuum decay per USP <1207>. Endotoxin is controlled at API release using LAL per USP <85>, with a typical parenteral limit of no more than 0.50 EU/mg for a 30 mg subcutaneous dose. If an isotonic solution is required, sodium chloride is added to an osmolality target of 270–320 mOsm/kg; the final solution should meet subvisible particle limits per USP <788>.

Process-scale sterile filtration of peptide solutions can display flux decay if the peptide forms soluble aggregates. Prefiltration through 0.45 µm membranes and controlled pH between 4.5 and 6.0 reduces aggregate load. The acetate counterion is preferred to trifluoroacetate for injectable grade because residual trifluoroacetate can modify pH and is less desirable in parenteral excipients. Stability of the formulated solution at 2–8 °C should be confirmed; if stored in prefilled syringes, extractables and leachables from the plunger and glass barrel must be assessed. The injectable grade is not supplied as a sterile product; it is a low-bioburden API intended for terminal aseptic filtration. The hold time between dissolution and sterile filtration should be minimized; solution stability studies define a maximum filtered-solution hold time. In production-scale filling, peristaltic pump shear can generate aggregates; tubing selection and pump speed must be qualified by size-exclusion HPLC before release.

Direct compression of icatibant acetate is complicated by the drug load and the cohesive nature of the lyophilized powder. Bulk density before granulation often falls below 0.35 g/cm³, and tapped density below 0.55 g/cm³; the resulting Carr index indicates poor to very poor flow. Roller compaction or wet granulation with hydroxypropyl cellulose or povidone is used to densify the API before capsule filling or tablet compression. Granule particle size is typically controlled at D₉₀ ≤ 850 µm for die fill consistency. The acetate salt is hygroscopic; processing should be conducted at controlled relative humidity, typically below 40% RH, to prevent sticking and water uptake. However, published data for oral icatibant tablet or capsule bioequivalence are limited; the molecule’s 1304 Da size, polar surface area, and susceptibility to gastrointestinal peptidases restrict oral permeability. No approved oral icatibant product exists, so oral grade development remains formulation-dependent and requires permeability enhancers, enteric targeting, or co-processed excipients.

Wet granulation with aqueous binder requires a preformulation stability screen because the peptide can hydrolyze in the presence of water at elevated temperature; granulation end-points should be below 35 °C product temperature unless data support higher temperatures. Dry granulation avoids water exposure but can generate fines that segregate during compression. For capsule filling, the granulate should be conditioned to 30–40% RH before filling to achieve a stable fill weight. These processing constraints are specific to the acetate salt and should not be transferred from smaller synthetic peptide APIs without experimental confirmation.

Comparative Position Against C1-Inhibitor and Plasma Kallikrein API Classes

Mechanistically, icatibant acetate blocks the bradykinin B2 receptor after subcutaneous administration; it does not replace C1 inhibitor or inhibit plasma kallikrein. This distinction is relevant during acute attacks where direct receptor antagonism provides rapid onset but a short terminal half-life of approximately 1.4 h after subcutaneous dosing. In contrast, plasma-derived C1-INH replacement has a longer circulating half-life but is sourced from human plasma and requires pathogen safety measures. Lanadelumab, a monoclonal antibody against plasma kallikrein, has a molecular weight near 146 kDa and is used for prophylaxis with extended dosing intervals. Berotralstat, an oral small molecule plasma kallikrein inhibitor with a molecular weight near 557.6 Da, provides once-daily oral administration but is differentiated by its target and hepatic metabolism profile.

In tablet and capsule process development, the major operational boundary is the peptide’s environmental sensitivity. Blending with lactose monohydrate or mannitol requires pre-drying at 40–50 °C and RH below 30% to maintain flow. Granulation with aqueous binders is generally avoided unless a stability study confirms that hydrolytic degradation remains below the specification threshold. For injectable grade, the main incompatibility is with strong oxidizing agents and high-pH buffers above pH 7.5, which may accelerate degradation of the thienylalanine residue. The API should not be processed with amine-based excipients in a solution state without forced degradation data, because primary amines can shift pH and react with peptide carbonyls. These operational boundaries define the route-specific use of the product and distinguish it from lower-molecular-weight synthetic inhibitors that allow conventional oral tablet formulation.